Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual


PR Newswire | Nov 24, 2020 08:01AM EST

Healthcare Conference

11/24 07:00 CST

Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference CAMBRIDGE, Mass., Nov. 24, 2020

CAMBRIDGE, Mass., Nov. 24, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference.

John P. Butler, President and Chief Executive Officer, and David A. Spellman, Senior Vice President and Chief Financial Officer, will participate in virtual one-on-one meetings on Thursday, December 3, 2020.

A recording of Akebia's conference presentation is available via the Piper Sandler conference site as well as on the Investors section of the Company's website at https://ir.akebia.com, from November 24 to December 3, 2020.

About Akebia TherapeuticsAkebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics ContactKristen K. Sheppard, Esq.ir@akebia.com

View original content to download multimedia: http://www.prnewswire.com/news-releases/akebia-therapeutics-to-participate-in-piper-sandler-32nd-annual-virtual-healthcare-conference-301179379.html

SOURCE Akebia Therapeutics






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC